The state of Florida currently has 136 active clinical trials seeking participants for Lymphoma research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL
NCT05138458
Recruiting
This is a Phase 1/2 study to test the safety, tolerability, and efficacy of the investigational agent MT-101 in patients with T cell Lymphoma. MT-101 is made with myeloid cells collected from the patient's blood. The myeloid cells are modified and later infused back into their veins. The modified myeloid cells recognize the tumor cells and are designed to target and kill them.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2023
Locations: Miami Cancer Institute at Baptist Health, Miami, Florida
Conditions: Cell Therapy, Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Adoptive Cellular Immunotherapy
Register for Updates
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
NCT04305444
Recruiting
Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma. However, single drug therapies have limitations, therefore, the current study is evaluating a novel oral combination of targeted drugs as a way of overcoming these limitations. This study will determine the efficacy of the triple combination therapy, DTRM-555, in patients with R/R CLL or R/R non-Hodgkin's lymphoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2023
Locations: Mayo Clinic, Jacksonville, Florida
Conditions: Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Richter's Transformation
Register for Updates
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04920617
Recruiting
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2023
Locations: Boca Raton Regional Hospital, Boca Raton, Florida +3 locations
Conditions: Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Register for Updates
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL
NCT04155710
Recruiting
This is a Phase 1/2, study evaluating IOV-2001 (Adoptive Cell Therapy) composed of autologous PBL (Peripheral Blood Lymphocytes) in patients with CLL/SLL, which has relapsed or is relapsing during treatment with ibrutinib or acalabrutinib.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
03/06/2023
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates